Fasting-like diet plus maintenance immunotherapy for non-progressing SCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether a fasting-like, calorie-restricted routine along with maintenance immunotherapy can help people with extensive-stage small-cell lung cancer (SCLC) who have not gotten worse after initial chemoimmunotherapy. If it works, it may help keep the cancer from progressing for longer and help maintain control after the first treatment phase.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old and able to follow all study visits, tests, and treatment instructions.
- Have confirmed small-cell lung cancer that has spread widely (extensive-stage).
- Have done 4 cycles of initial treatment with atezolizumab plus carboplatin and etoposide, and your cancer must not have progressed on the most recent scans (started maintenance within 6 weeks of the last cycle).
- Have enough stored tumor sample from a prior biopsy/procedure (archival tumor tissue).
- Be medically strong enough for treatment (good bone marrow and organ function) and able to perform daily activities at level 0–2 on the ECOG scale.
- Be willing to do a 5-day cyclic calorie restriction routine exactly as prescribed (fasting-like regimen).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus standard chemotherapy and radiation for people with extensive-stage small cell lung cancer that has only spread to a few places. The goal is to see if this approach can help control the cancer better.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
This trial tests whether adding radiation therapy to the chest during maintenance immunotherapy can help people with extensive-stage small cell lung cancer live longer. You may be eligible if you've already had chemotherapy plus immunotherapy and your cancer has shrunk or stayed stable.
This study tests a combination of an oral targeted therapy (anlotinib) with a liposomal form of chemotherapy and an immunotherapy drug as maintenance treatment for extensive-stage small cell lung cancer after initial treatment. It aims to keep the cancer from growing again.
This study tests a new maintenance therapy (adebrelimab plus apatinib) for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy and immunotherapy. The goal is to help keep the cancer from coming back longer.
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.